Exhibit 1

Request for Special Temporary Authority

1. Introduction

By the instant application ("Application"), Nyxoah Inc. ("Nyxoah") requests that the Commission grant a six month Experimental Special Temporary Authority (STA) to operate the facilities (the "Facilities") specified in the instant application.

2. Purpose of the Operation

Pursuant to 47 CFR 5.3(i) ("*Testing of medical devices that use RF wireless technology or communications functions for diagnosis, treatment, or patient monitoring.*"), Nyxoah seeks STA to operate its "Genio 2.1 System" (the "System"), intended for bilateral neurostimulation Obstructive Sleep Apnea (OSA) therapy during clinical trials that are expected to involve approximately 134 patients nationwide. STA granted for a period 6 months is appropriate because all implantations are expected to be complete by Q1 2022 and all activation visits are expected to be complete by the end of May 2022.

Transmitter #1: Activation Chip (AC)

The AC is a transmitter which, upon connection to a disposable patch antenna, generates energy to the IS for activation of stimulation according to customized stimulation parameters. This device acts like a wireless 'power supply' to the Implant, but does not communicate with the Implant.

Transmitter #2: External Stimulator (ES)

The ES is used by a surgeon to stimulate the IS during implantation by sending modulated wireless energy to the implant, thereby allowing a surgeon to visually evaluate muscle contraction during stimulation, and to evaluate the implant's anatomical location during the implantation.

3. Station ID Waiver Requested

A waiver of the Station ID requirements of 47 CFR §5.115(a) is respectfully requested.

4. Notes Regarding Transmissions, Mean/Peak, Tolerances, Modulation

Frequencies Transmitted:

- Both of the above devices – the AC and the ES - use an 8MHz electromagnetic field emission to transfer the energy to the Implant.

- The AC utilizes Bluetooth (2.4 GHz) in the sleep lab environment as well as to facilitate communications with a dedicated smartphone application to allow the patient to control treatment and adjust treatment amplitude to facilitate patient compliance with the treatment.

Summary of Transmitting Equipment:

Device	Manufacturer	Model No.	# Units	Experimental?
AC 2364	Nyxoah	NX-ASM-002325	200	Yes
ES	Nyxoah	NX-ASM-00659	200	Yes

Mean/Peak, Tolerance, Modulation

Device	Mean/Peak	Tolerance	Modulating Signal
AC	8 MHz – Quasi Peak* 2.4 GHz - Mean	Frequency Drift = 7.838KHz	The AC comprises an ON/OFF cycle as follows: ON cycle max = OFF cycle max = 10Sec. During the ON cycle the Pulse max width = 250uSec and Frequency = 50Hz
ES	8 MHz – Quasi Peak*	Not Available	The ES comprises an ON/OFF cycle as follows: ON cycle = OFF cycle = 2Sec. During the ON cycle the Pulse width = 120uSec and Frequency = 35Hz.

* Note that the STA Form only allows a reply of "Peak" or "Mean", and as such "Peak" was inserted into the Form. However, this is to confirm that the power levels reported are actually "Quasi Peak" in nature as specified in the chart above.

5. Nationwide Authority Requested

Nationwide authority is requested because once the 134 patients receive the Implant at their assigned medical facility and have their AC stimulation settings programmed at a sleep lab, the patients will disburse to their various homes and live their lives on a normal basis, including the possibility of travel, etc. During the clinical trial, patients will return to their hospital and/or sleep lab at designated intervals for follow-up evaluations by clinicians.

6. Grant of STA is in the Public Interest

The System is designed to treat patients with moderate to severe Obstructive Sleep Apnea (OSA), the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression, and stroke. In basic terms, the System is designed to stimulate the Hypoglossal nerve in order to contract the Genioglossus muscle (the base of the tongue) in order to open the patient's upper airway preventing obstruction of the airway and allowing normal breathing during a night sleep.

Experimental license grant will allow healthcare providers to treat OSA patients and review the System in a clinical trial setting. The System's benefits

include a simplified battery-less and software-less neurostimulator, and reduction of the complexity of the invasive surgical procedure compared to competing technologies. The implant is only functional when externally powered and does not affect the patient's daily routine. A dedicated smartphone application allows the patient to control treatment and adjust treatment amplitude to facilitate patient compliance with the treatment by communicating with the AC over Bluetooth.

7. Interference Mitigation

Nyxoah is aware of its obligations under Part 5 of the Commission's rules to avoid interference to co-channel licensees in non-experimental services and will take all steps to ensure compliance with this obligation. The risk of harmful interference, even with nationwide licensing, should be extraordinarily low and indeed interference to any licensed communications would hardly be possible. In addition, the following factors will help mitigate any interference issues:

General Mitigation Factors:

- Both the AC and ES emit very low RF transmission power
- The ISM band frequency (8MHz) is centered and narrow banded
- The system has an extremely short operation range
  (AC - max 4cm ; ES - max2cm)
- All RF transmission is directed into a user's body

AC-Specific Mitigation Factors:

- Used only in a home (indoor) environment
- Transmitted power ERP @ 8MHz is 0.691mW
- Low bandwidth transmission @ 8MHz of [24.1] kHz
- Incorporate BLE (Bluetooth Low Energy) that provides considerably reduced power consumption and shorter ranges

ES-Specific Mitigation Factors:

- Used only in a health-care controlled (indoor) environment
- Transmitted power 118.6nW
- Low bandwidth transmission 27 kHz

8. Stop Buzzers

The following will be available by wireless telephone and will act as the "stop buzzer" if any issues arise during testing:

PRIMARY:	Dvir Itzhakov:	972-54-3000369
SECONDARY:	Nathalie:	972-50-6992595